Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B

Bristol Myers Squibb is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for a rare type of heart disease is on track for an FDA submission and is projected to become a blockbuster seller, if approved. According to financial terms announced Monday, Bristol (NYSE: BMY) […]

Click to view original post